Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy

Biological Psychiatry

Volumn 41, Issue 2, 1997, Pages 135-144

  Kornhuber, Johannes ^a,c   Weller, M ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

amantadine; glutamate; low affinity NMDA receptor antagonist; memantine; MK 801; N methyl D aspartate (NMDA); neuroprotection; phencyclidine (PCP); psychosis

Indexed keywords

AMANTADINE; DIZOCILPINE; GLUTAMATE RECEPTOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT; PHENCYCLIDINE;

ALZHEIMER DISEASE; EPILEPSY; HUMAN; NERVE CELL DEGENERATION; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0031048111     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00047-9     Document Type: Article

References (84)

1. Altamura AC, Buccio M, Colacurcio F, Colombo G, Terzi A (1986): Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol. Acta Neural Napoli 8:19-26.
2. Andine P, Sandberg M, Bagenholm R, Lehmann A, Hagberg H (1991): Intra-and extracellular changes of amino acids in the cerebral cortex of the neonatal rat during hypoxic-ischemia. Dev Brain Res 64:115-120.
3. Arendash GW, Millard WJ, Dunn AJ, Meyer EW (1987): Long-term neuro-pathological and neurochemical effects of nucleus basalis lesions in the rat. Science 238:952-956.
4. Aylward M, Maddock J, Davies DE, Protheroe DA, Leideman T (1984): Dextromethorphan and codeine: comparison of plasma kinetic and antitussive effects. Eur J Respirat Dis 65:283-291.
5. Behl C, Rupprecht R, Skutella T, Holsboer F (1995): Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro. NeuroReport 7:360-364.
6. Benveniste H, Drejer J, Schousboe A, Diemer NH (1984): Elevations of extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 43:1369-1374.
7. Bliss TVP, Collingridge GL (1993): A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39.
8. Bormann J (1989): Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166:591-592.
9. Bouvier M, Szatkowski M, Amato A, Attwell D (1992): The glial cell glutamate uptake carrier countertransports pH-changing anions. Nature 360:471-474.
10. Bresink I, Danysz W, Parsons CG, Mutschler E (1995): Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology 34:533-540.
11. Butzer JF, Silver DE, Sahs AL (1975): Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 25:603-606.
12. Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992): Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12:4427-4436.
13. Clark WM, Coull BM (1994): Randomized trial of CGS19755, a glutamate antagonist, in acute ischemic stroke treatment. Neurology 44 (Suppl 2):A270.
14. Clements JD, Lester RAJ, Tong G, Jahr CE, Westbrook GL (1992): The time course of glutamate in the synaptic cleft. Science 258:1498-1501.
15. Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS (1962): Comparison of phencyclidine hydrochloride (sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (amytal) sodium; II. Symbolic and sequential thinking. Arch Gen Psychiatry 6:395-401.
16. Contin M, Riva R, Albani F, Baruzzi A (1987): Simple and rapid GLC method for the determination of orphenadrine in human plasma. Biomed Chromatogr 2:193-194.
17. De Boni U, McLachlan DRC (1985): Controlled induction of paired helical filaments of the Alzheimer type in cultured human neurons, by glutamate and aspartate. J Neural Sci 68:105-118.
18. Ditzler K (1991): Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung/ Drug Res 41:773-780.
19. Dragunow M, Faull RLM, Lawlor P, Beilharz EJ, Singleton K, Walker EB, Mee E (1995): In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. NeuroReport 6:1053-1057.
20. Gerlach M, Riederer P, Przuntek H, Youdim MBH (1991): MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol Mol Pharmacol Sect 208:273-286.
21. Görtelmeyer R, Erbler H (1992): Memantine in the treatment of mild to moderate dementia syndrome. A double-blind place-bo-controlled study. Arzneimittelforschung/Drug Res 42:904-913.
22. Greenamyre JT, Penney JB, Young AB, D'Amato CJ, Hicks SP, Shoulson I (1985): Alterations in glutamate binding in Alzheimer's and Huntington's disease. Science 227:1496-1499.
23. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB (1988): Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 12: 421-430.
24. Grossmann W, Schütz W (1982): Memantin und neurogene Blasenstörungen im Rahmen spastischer Zustandsbilder. Arzneimittelforschung/Drug Res 32:1273-1276.
25. Jackisch R, Kruchen A, Sauermann W, Hertting G, Feuerstein TJ (1994): The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur J Pharmacol 264:207-211.
26. 2+ channels. Neurosci Lett 105:227-232.
27. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
28. Jorgensen HA, Andreassen OA (1995): Memantine inhibits the development of haloperidol-induced persistent oral movements in rats. Soc Neurosci Abstr 21:470.
29. Kitamura Y, Zhao X-H, Takei M, Yonemitsu O, Nomura Y (1991): Effects of antidepressants on the glutamatergic system in mouse brain. Neurochem Int 19:247-253.
30. Klockgether T, Jacobson P, Löschmann P-A, Turski L (1993): The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm Park Dis Dement Sect 5:101-106.
31. Koh J-Y, Yang LL, Cotman CW (1990): β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533:315-320.
32. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166:589-590.
33. 3H]MK-801 binding sites in post-mortem human frontal cortex. Eur J Pharmacol 162:483-490.
34. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991): Effects of the l-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 206:297-300.
35. Kornhuber J, Schoppmeyer K, Riederer P (1993): Affinity of l-aminoadamantanes for the σ binding site in post-mortem human frontal cortex. Neurosci Lett 163:129-131.
36. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994): Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43:91-104.
37. Kornhuber J, Herr B, Thome J, Riederer P (1995a): The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J Neural Transm Suppl 46:127-133.
38. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P (1995b): Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: Binding and patch clamp studies. J Neural Transm Gen Sect 102:237-246
39. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P (1995c): Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34:713-721.
40. Kornhuber J, Quack G (1995): Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195:137-139.
41. Kornhuber J, Weller M (1993): Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm Gen Sect 92:57-65.
42. Kornhuber J, Weller M (1995): Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists. In Fog R, Gerlach J, Hemmingsen R, Krogsgaard-Larsen P, Thaysen JH (eds), Schizophrenia - An Integrated View. Alfred Benzon Symposium 38. Copenhagen: Munksgaard, pp 314-325.
43. König P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H (1995): Amantadine versus biperiden: A double-blind study of treatment-efficacy in neuroleptic EPS. Neuropsychobiology 33:80-84
44. Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M, Mishina M (1992): Molecular diversity of the NMDA receptor channel. Nature 358:36-41.
45. Labout JJ, Thijssen CT, Keijser GG, Hespe W (1982): Difference between single and multiple dose pharmacokinetics of or-phenadrine hydrochloride in man. Eur J Clin Pharmacol 21:343-350.
46. LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G (1995): The Alzheimer's Aß peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nature Genetics 9:21-30.
47. Lassmann H, Bancher C, Breitschopf H, Weigiel J, Bobinski M, Jellinger K, Wisniewski HM (1995): Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 89:35-41.
48. Lipton SA (1993): Neuroprotective effects of memantine. Reply. Neurology 43:1054-1055.
49. Lucas DR, Newhouse JP (1957): The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol 58:193-201.
50. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992): beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12:376-389.
51. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH (1992): Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256:1217-1221.
52. Mundinger F, Milios E (1985): Erfahrungen mit Memantine bei der Behandlung schwerer spastischer und extrapyramidaler Bewegungsstörungen in Kombination mit der stereotaktischen Operation. Nervenarzt 56:106-109.
53. Müller WEG, Schröder HC, Ushijima H, Dapper J, Bormann J (1992): gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: Prevention by memantine. Eur J Pharmacol 226: 209-214.
54. Nakanishi S (1992): Molecular diversity of glutamate receptors and implications for brain function. Science 258:597-603.
55. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988): Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451:205-212.
56. Olney JW (1978): Neurotoxicity of excitatory amino acids. In McGeer EG, Olney JW, McGeer PL (eds), Kainic Acid as a Tool in Neurobiology. New York: Raven Press, pp 95-121.
57. Olney JW, Price MT, Labruyere J, Salles KS, Friedrich G, Mueller M, Silverman E (1987): Anti-parkinsonian agents are phencyclidine agonists and N-methyl-D-aspartate antagonists. Eur J Pharmacol 142:319-320.
58. Oye I, Paulsen O, Maurset A (1992): Effects of ketamine on sensory perception: evidence for a role of N-methyl-Daspartate receptors. J Pharmacol Exp Ther 260:1209-1213.
59. Parkes JD, Zilkha KJ, Calver DM, Knill-Jones RP (1970): Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet I:259-262.
60. Parsons CG, Grüner R, Rozental J, Millar J, Lodge D (1993): Patch clamp studies on the kinetic and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32: 1337-1350.
61. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA (1996): Comparative patch clamp studies with freshly dissociated rat hippocampal and striatal neurones on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 8:446-454
62. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995): Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258.
63. Perry PJ, Pfohl BM, Holstad SG (1987): The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinetics 13:381-392.
64. 3H]MK801 binding to the N-methyl-D-aspartate receptor reveals drug interactions with the zinc and magnesium binding sites. J Pharmacol Exp Ther 247:1025-1031.
65. Rogawski MA, Yamaguchi S, Blake PA, Jones SM, Bieda MC, DeCosta BR, Thurkauf A (1992): Anticonvulsant 1-phenyl-cycloalkylamine analogs: Uncompetitive NMDA antagonists with low motor toxicity. In: Kamenka JM, Domino EF (eds), Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection. Ann Arbor: NPP Books, pp 747-758.
66. Rogawski MA (1993): Therapeutic potential of excitatory amino acid antagonists: Channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 14:325-331.
67. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D (1959): Comparison of sernyl with other drugs. Simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. Arch Gen Psychiatry 1:651-656.
68. Schwab RS, England AC, Poskanzer DC, Young RR (1969): Amantadine in the treatment of Parkinson's disease. JAMA 208:1168-1170.
69. Sills MA, Loo PS (1989): Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate. Mol Pharmacol 36:160-165.
70. Silvasti M, Karttunen P, Tukiainen H, Kokkonen P, Hänninen U, Nykänen S (1987): Pharmacokinetics of dextromethorphan and dextrorphan: A single dose comparison of three preparations in human volunteers. Int J Clin Pharm Ther Toxicol 25:493-497.
71. Silver H, Geraisy N, Schwartz M (1995): No difference in the effect of biperiden and amantadine on Parkinsonian - and tardive dyskinesia - type involuntary movements: A double blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 56:167-170. [published erratum J Clin Psychiatry 56 (1995) 435].
72. Silver H, Geraisy N, Schwartz M (1995): No difference in the effect of biperiden and amantadine on Parkinsonian - and tardive dyskinesia - type involuntary movements: A double blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 56:167-170. [published erratum J Clin Psychiatry 56 (1995) 435].
73. Sonsalla PK, Zeevalk GD, Manzino L, Giovanni A, Nicklas WJ neuropathology produced by systemic l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral l-methyl-4-phenylpyridinium. J Neurochem 58:1979-1982.
74. Su JH, Anderson AJ, Cummings PJ, Cotman CW (1994): Immunohistochemical evidence for apoptosis in Alzheimer's disease. NeuroReport 5:2529-2533.
75. Sveinbjornsdottir S, Sander JWAS, Upton D, et al (1993): The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 16:165-174.
76. Szatkowski M, Attwell D (1994): Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 17:359-365.
77. Teitelbaum JS, Zatorre RJ, Carpenter S, Gendron D, Evans AC, Gjedde A, Cashman NR (1990): Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 322:1781-1787.
78. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349:414-418.
79. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Ho MM, Prasad M, Rajput A, Basran P (1993): Amantadine treatment is an independent predictor of improved survival in Parkinsonism. Can J Neural Sci 20:235.
80. Weller M, Finiels-Marlier F, Paul SM (1993a): NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: Neuroprotective properties of amantadine and memantine. Brain Res 613:143-148.
81. Weller M, Marini AM, Finiels-Marlier F, Martin B, Paul SM (1993b): MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. Eur J Pharmacol Environ Toxicol Pharmacol Sect 248:303-312.
82. Weller M, Paul SM (1993): 3-Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons. Eur J Pharmacol Environ Toxicol Pharmacol Sect 248:223-228.
83. Whiteman PD, Fowle AS, Hamilton MJ, Peck AW, Bye A, Dean K, Webster A (1985): Pharmacokinetics and pharmacodynamics of procyclidine in man. Eur J Clin Pharmacol 28:73-78.
84. Zech K, Sturm E, Ludwig G (1985): Pharmacokinetics and metabolism of budipine in animals and humans. In Gersten-brand F, Poewe W, Stern G (eds), Clinical Experiences With Budipine in Parkinson Therapy. Berlin: Springer, pp 113-121.